Stealth Therapeutics Inc. on Tuesday will begin a trial at two Wisconsin health care organizations to determine the best potential market for the company’s Invisiport, a vascular access port that is implanted under the skin in a patient’s arm.

Read the full Milwaukee Journal Sentinel story here.